Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease.
J Crohns Colitis
; 14(12): 1780-1784, 2020 Dec 02.
Article
in English
| MEDLINE | ID: covidwho-1672170
ABSTRACT
BACKGROUNDS AND AIMS:
We aimed to evaluate the safety of Bacille Calmette-Guérin [BCG] vaccination in infants born to mothers receiving anti-tumour necrosis factor [anti-TNF] therapy for inflammatory bowel disease.METHODS:
Adverse events of BCG vaccination were evaluated in 90 infants who were last exposed to anti-TNF agents at a median of gestational week 30.RESULTS:
After receiving BCG vaccination at a median age of 6 months [range, 0.25-11 months], three infants [3.3%] showed injection site swelling, two of whom also showed axillar lymphadenopathy. The rates of adverse events were similar between infants who were last exposed to anti-TNF agents before the third trimester [nâ =â 35] and those who were last exposed in the third trimester [nâ =â 55] [2.9% vs 3.6%; pâ =â 1.00]. All adverse events were spontaneously resolved and there were no serious adverse events such as active tuberculosis infection or death.CONCLUSIONS:
BCG vaccination after 6 months of age is of low risk in infants exposed to anti-TNF agents in utero.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia
/
BCG Vaccine
/
Inflammatory Bowel Diseases
/
Tumor Necrosis Factor Inhibitors
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Female
/
Humans
/
Infant
/
Male
/
Infant, Newborn
Language:
English
Journal:
J Crohns Colitis
Journal subject:
Gastroenterology
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS